RecruitingNCT05011045

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Sponsor

M.D. Anderson Cancer Center

Enrollment

100 participants

Start Date

Jan 9, 2020

Study Type

OBSERVATIONAL

Conditions

Hematopoietic and Lymphoid Cell Neoplasm Lymphoma Leukemia Central Nervous System Lymphoma Plasma Cell Myeloma Secondary Central Nervous System Lymphoma

Summary

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

Age 18 years or older
Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary central nervous system lymphoma \[SCNSL\], leukemia, myeloma)
Proficient and capable of completing tests in English
Patients with claustrophobia are eligible if the claustrophobia is managed with medication
Patients with cognitively-impairment are eligible if the impairment is managed with medication
Patients who are pregnant